link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of...

27
Tabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23- H1 cyt. staini ng NM23-H1 nuc. Age at diagn osis Race Gleason score Positi ve nodes (n) pt stage pN stag e pM stag e PSA recurre nce status Prost atect omy age (year s) PSA recurrence (months) Months PSA recurrence free months surviva l PSA recurrenc e status survival G1 2 1 67 Caucasia n 6 0 pT3a pN0 pMX No Recurre nce 67 33 33 0 G10 0 0 60 Caucasia n 7 0 pT3b pN0 pM0 Never disease free 60 Never disease free G11 0 0 71 Caucasia n 7 0 pT2b pN0 pMX Unknown 72 G12 0 0 44 Other 8 2 pT3a pN1 pMX Unknown 44 G13 0 0 67 Caucasia n 6 0 pT3a pN0 pM0 Unknown 68 G14 2 1 68 African American 7 0 pT2b pN0 pM0 Unknown 68 G15 0 0 68 Caucasia n 7 1 pT3b pN1 pMX No Recurre nce 69 16 16 0 G16 3 1 57 Caucasia n 7 0 pT2b pN0 pM0 Unknown 57 G17 0 0 67 Caucasia n 7 0 pT3a pN0 pM0 Never disease free 67 Never disease free G18 3 3 60 Caucasia n 8 0 pT3b pN0 pMX Never disease 60 Never disease

Transcript of link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of...

Page 1: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

Tabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs

Tissue code

NM23-H1 cyt.

staining NM23-

H1 nuc.Age at diagno

sisRace Gleason

scorePositive nodes

(n)pt

stagepN

stagepM

stage

PSA recurren

ce status

Prostatectomy

age (years)

PSArecurrence(months)

Months PSA recurrence

freemonthssurvival

PSA recurrence

status survival

G1 2 1 67 Caucasian 6 0 pT3a pN0 pMXNo

Recurrence

67 33 33 0

G10 0 0 60 Caucasian 7 0 pT3b pN0 pM0Never

disease free

60 Never disease free

G11 0 0 71 Caucasian 7 0 pT2b pN0 pMX Unknown 72

G12 0 0 44 Other 8 2 pT3a pN1 pMX Unknown 44

G13 0 0 67 Caucasian 6 0 pT3a pN0 pM0 Unknown 68

G14 2 1 68 African American 7 0 pT2b pN0 pM0 Unknown 68

G15 0 0 68 Caucasian 7 1 pT3b pN1 pMXNo

Recurrence

69 16 16 0

G16 3 1 57 Caucasian 7 0 pT2b pN0 pM0 Unknown 57

G17 0 0 67 Caucasian 7 0 pT3a pN0 pM0Never

disease free

67 Never disease free

G18 3 3 60 Caucasian 8 0 pT3b pN0 pMXNever

disease free

60 Never disease free

G19 3 3 58 Caucasian 6 0 pT2b pN0 pM0Never

disease free

58 Never disease free

Page 2: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

G2 1 1 68 Caucasian 6 0 pT2b pN0 pMX Unknown 68

G20 1 3 70 Other 5 0 pT2b pN0 pMX Unknown 70

G21 2 2 62 Caucasian 7 0 pT2b pN0 pM0 Recurred 62 19 19 1

G22 2 2 57 Caucasian 7 0 pT2b pN0 pMX Unknown 57

G23 3 3 57 Asian 7 0 pT3b pN0 pMX Unknown 58

G24 3 0 46 Caucasian 6 0 pT2a pN0 pMXNo

Recurrence

47 62 62 0

G25 3 0 48 Caucasian 6 0 pT2a pN0 pMX Recurred 48 40 40 1

G26 3 0 68 Caucasian 8 0 pT3b pN0 pMX Unknown 68

G27 3 0 74 African American 6 0 pT3a pN0 pMX

Never disease

free74 Never

disease free

G28 2 0 72 Caucasian 7 0 pT3b pN0 pMXNever

disease free

72 Never disease free

G29 3 3 66 Caucasian 9 0 pT3b pN0 pMXNo

Recurrence

66 9 9 0

G3 0 0 67 Caucasian 6 0 pT3a pN0 pMXNo

Recurrence

68 119 119 0

G30 2 0 58 African American 6 0 pT3b pNX pMX

Never disease

free58 Never

disease free

G31 2 0 67 Caucasian 6 0 pT2b pN0 pMXNo

Recurrence

67 110 110 0

G32 0 0 74 Caucasian 7 0 pT2b pNX pMX No 74 28 28 0

Page 3: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

Recurrence

G33 2 0 70 African American 7 0 pT2b pNX pMX Unknown 70

G34 0 0 64 Caucasian 7 0 pT3b pNX pMX Unknown 64

G35 2 1 70 Caucasian 7 0 pT2b pN0 pMX Unknown 70

G36 3 2 59 African American 7 0 pT3b pN0 pMX

Never disease

free59 Never

disease free

G37 0 0 64 Caucasian 6 0 pT2b pN0 pMX Recurred 64 24 24 1

G38 2 0 66 Caucasian 7 0 pT3a pN0 pMXNever

disease free

66 Never disease free

G39 0 0 61 Caucasian 9 0 pT2b pN0 pMXNever

disease free

61 Never disease free

G4 2 0 68 Caucasian 6 0 pT2b pN0 pMX Unknown 68

G40 2 0 68 African American 6 0 pT2b pN0 pMX Unknown 68

G41 1 0 66 Caucasian 6 0 pT2b pN0 pMXNever

disease free

66 Never disease free

G42 2 0 66 Caucasian 6 0 pT2a pN0 pMXNever

disease free

66 Never disease free

G43 2 2 60 Caucasian 9 0 pT2b pN0 pMX Recurred 60 15 15 1

G44 0 0 66 Caucasian 6 0 pT2b pN0 pMX Unknown 66

Page 4: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

G45 3 2 58 Caucasian 7 0 pT2b pN0 pMXNever

disease free

58 Never disease free

G46 0 0 64 African American 6 0 pT2b pN0 pMX

Never disease

free65 Never

disease free

G47 0 0 56 Caucasian 6 0 pT2b pN0 pMXNo

Recurrence

56 126 126 0

G48 1 2 58 Caucasian 6 0 pT2b pN0 pMXNever

disease free

58 Never disease free

G49 3 2 53 Caucasian 8 0 pT2b pN0 pMXNever

disease free

53 Never disease free

G5 1 0 70 Caucasian 7 0 pT2b pN0 pMXNever

disease free

70 Never disease free

G50 2 1 66 Caucasian 7 0 pT2b pN0 pMXNever

disease free

66 Never disease free

G51 3 1 71 Caucasian 7 0 pT2a pN0 pMX Unknown 71

G52 3 1 66 Caucasian 7 0 pT2b pN0 pMX Unknown 66

G53 0 0 58 African American 6 0 pT2b pN0 pMX Recurred 58 58 58 1

G54 0 0 58 Caucasian 6 0 pT2a pN0 pMXNever

disease free

58 Never disease free

G55 2 1 71 Caucasian 7 0 pT2b pN0 pMX Unknown 71

Page 5: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

G56 0 0 66 Caucasian 7 0 pT2a pNX pMXNever

disease free

66 Never disease free

G57 0 0 65 African American 7 0 pT2b pN0 pMX Unknown 65

G58 0 0 67 African American 7 0 pT2b pNX pMX Unknown 67

G59 3 1 67 Caucasian 8 0 pT2b pNX pMXNever

disease free

68 Never disease free

G6 2 1 59 Caucasian 6 0 pT3a pN0 pM0 Unknown 59

G60 3 2 58 Caucasian 7 1 pT2b pN1 pMX Unknown 58

G61 3 1 65 Caucasian 7 0 pT3b pN0 pMX Unknown 65

G62 1 1 67 Caucasian 6 0 pT2b pN0 pMXNever

disease free

67 Never disease free

G63 1 1 71 Caucasian 6 0 pT2b pNX pMX Unknown 72

G64 3 2 75 African American 7 0 pT2b pN0 pMX

Never disease

free75 Never

disease free

G65 0 1 63 African American 7 0 pT2b pN0 pMX Unknown 63

G66 0 0 56 African American 7 0 pT3b pN0 pMX Unknown 56

G67 0 0 69 African American 6 0 pT3a pN0 pMX

No Recurren

ce69 111 111 0

G68 3 2 73 African American 7 0 pT2 pN0 pM0 Unknown 73

Page 6: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

G69 0 0 71 African American 7 1 pT3a pN1 pMX Unknown 72

G7 3 2 53 African American 6 0 pT2b pN0 pMX

Never disease

free53 Never

disease free

G70 2 0 52 African American 8 0 pT3 pN0 pM0 Unknown 52

G71 3 0 63 African American 5 0 pT3b pN0 pM0 Unknown 63

G72 0 0 61 African American 5 0 pT1 pN0 pM0 Unknown 61

G73 0 0 56 African American 7 0 pT3 pN0 pM0

No Recurren

ce56 124 124 0

G8 0 0 69 African American 7 0 pT3a pN0 pM0

Never disease

free70 Never

disease free

G9 0 0 63 Caucasian 6 0 pT2a pN0 pMXNever

disease free

63 Never disease free

M1 0 0 71 Caucasian 7 0 pT2b pN0 pMX Unknown 71

M10 3 1 72 Caucasian 7 0 pT3a pN0 pMXNo

Recurrence

72 67 67 0

M100 0 0 66 Caucasian 6 0 pT2 pN0 pMX Unknown 66

M101 0 1 70 Caucasian 6 0 pT2 pN0 pMX Unknown 70

M102 0 0 67 Caucasian 7 0 pT2b pN0 pM0 Unknown 67

M103 0 0 62 African American 7 0 pT2 pN0 pM0 Unknown 62

Page 7: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

M104 2 1 58 Caucasian 7 0 pT3a pN0 pM0 Recurred 58 83 83 1

M105 0 0 67 Caucasian 6 0 pT2 pN0 pMXNo

Recurrence

68 167 167 0

M106 2 0 69 Caucasian 6 0 pT2b pN0 pM0No

Recurrence

69 76 76 0

M107 2 0 66 Caucasian 7 0 pT2b pN0 pM0 Recurred 67 43 43 1

M108 3 1 63 Caucasian 7 0 pT3a pN0 pMX Recurred 63 16 16 1

M109 2 1 66 Caucasian 7 1 pT3b pN1 pMX Unknown 66

M11 2 0 60 Caucasian 7 0 pT3b pN0 pMX Recurred 60 105 105 1

M110 3 2 73 Caucasian 7 0 pT2b pN0 pM0No

Recurrence

74 150 150 0

M111 3 0 47 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

47 17 17 0

M12 2 0 74 Caucasian 6 -1 pT2b pNX pMX Unknown 74

M13 2 0 69 Caucasian 6 0 pT2b pN0 pMX Unknown 69

M14 3 0 66 Caucasian 7 0 pT2b pN0 pMXNever

disease free

66 Never disease free

M15 0 0 62 Caucasian 8 0 pT3b pN0 pMXNever

disease free

62 Never disease free

M16 2 0 70 Caucasian 7 0 pT2b pN0 pMX Unknown 70

M17 0 0 69 Caucasian 7 0 pT2b pN0 pMX No 69 131 131 0

Page 8: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

Recurrence

M18 2 0 67 Caucasian 7 0 pT3a pN0 pMXNever

disease free

67 Never disease free

M19 3 0 65 Caucasian 6 0 pT2b pN0 pMX Recurred 65 30 30 1

M2 2 0 71 Caucasian 7 0 pT2b pN0 pMX Unknown 71

M20 0 0 57 Caucasian 6 0 pT2a pN0 pMXNever

disease free

57 Never disease free

M21 3 0 57 Caucasian 7 0 pT2b pN0 pMXNever

disease free

57 Never disease free

M22 3 0 65 Caucasian 6 0 pT2b pN0 pMXNo

Recurrence

65 156 156 0

M23 3 0 63 Caucasian 7 0 pT2b pN0 pMXNever

disease free

63 Never disease free

M24 3 2 63 Caucasian 7 0 pT2b pN0 pMX Unknown 63

M25 1 0 59 Caucasian 7 0 pT3a pN0 pMXNever

disease free

60 Never disease free

M26 0 0 78 Caucasian 8 0 pT2b pN0 pMXNo

Recurrence

78 30 30 0

M27 3 1 66 Caucasian 6 0 pT2 pN0 pMXNo

Recurrence

66 131 131 0

M28 2 0 62 Caucasian 7 0 pT2b pN0 pMX No Recurren 62 152 152 0

Page 9: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

ce

M29 1 0 55 Caucasian 6 0 pT2b pN0 pMXNo

Recurrence

56 155 155 0

M3 2 1 65 Caucasian 6 0 pT2b pN0 pMXNever

disease free

65 Never disease free

M30 2 1 71 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

71 82 82 0

M31 3 0 67 Caucasian 7 0 pT3b pN0 pMX Recurred 67 33 33 1

M32 1 0 52 Caucasian 7 0 pT2b pN0 pMX Recurred 53 34 34 1

M33 2 0 70 Caucasian 7 0 pT3b pN0 pMX Recurred 70 103 103 1

M34 2 1 69 Caucasian 7 0 pT3a pN0 pMXNo

Recurrence

69 76 76 0

M35 0 0 65 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

65 130 130 0

M36 2 1 59 Caucasian 6 0 pT2 pN0 pMXNo

Recurrence

59 68 68 0

M37 3 2 66 Caucasian 6 0 pT2b pN0 pMXNo

Recurrence

66 123 123 0

M38 3 0 60 Caucasian 6 0 pT2b pN0 pMX Unknown 60

M39 3 0 62 Caucasian 7 0 pT3b pN0 pMX Recurred 62 43 43 1

M4 2 2 65 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

65 131 131 0

M40 2 0 58 Caucasian 7 0 pT3a pN0 pMX Recurred 58 83 83 1

Page 10: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

M41 2 0 54 Caucasian 6 0 pT2b pN0 pMXNo

Recurrence

54 23 23 0

M42 2 1 63 Caucasian 7 0 pT3a pN0 pMXNo

Recurrence

63 9 9 0

M43 2 1 61 Caucasian 7 0 pT3a pN0 pMXNever

disease free

61 Never disease free

M44 2 1 69 Caucasian 7 0 pT3a pN0 pMXNever

disease free

69 Never disease free

M45 2 0 69 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

69 20 20 0

M46 3 0 63 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

64 138 138 0

M47 2 0 60 African American 7 0 pT2b pN0 pMX

No Recurren

ce60 141 141 0

M48 3 0 64 Caucasian 7 0 pT2b pN0 pMX Unknown 64

M49 3 0 57 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

57 21 21 0

M5 2 2 69 Caucasian 7 1 pT3b pN1 pMXNever

disease free

69 Never disease free

M50 2 1 66 African American 7 0 pT3b pN0 pMX

Never disease

free66 Never

disease free

M51 2 1 59 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

59 25 25 0

Page 11: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

M52 1 0 78 Caucasian 7 0 pT3b pN0 pMXNever

disease free

78 Never disease free

M53 0 0 67 Caucasian 7 0 pT2a pN0 pMXNo

Recurrence

67 163 163 0

M54 0 0 68 African American 7 0 pT2b pN0 pMX Unknown 68

M55 2 1 64 Caucasian 6 0 pT3a pN0 pMXNever

disease free

64 Never disease free

M56 2 0 69 Caucasian 6 0 pT2b pN0 pMXNo

Recurrence

69 101 101 0

M57 2 1 42 Caucasian 7 0 pT3a pN0 pMX Recurred 42 8 8 1

M58 2 1 55 Caucasian 7 0 pT2b pN0 pMX Recurred 55 130 130 1

M59 2 0 61 Caucasian 7 0 pT3a pN0 pMXNever

disease free

61 Never disease free

M6 3 2 59 Caucasian 7 0 pT3b pN0 pMXNever

disease free

59 Never disease free

M60 2 0 58 Caucasian 6 0 pT2b pN0 pMX Recurred 58 14 14 1

M61 2 0 59 Caucasian 7 0 pT2b pN0 pMX Unknown 59

M62 2 0 62 Caucasian 6 0 pT2 pN0 pMX Unknown 62

M63 0 0 73 Caucasian 6 0 pT3a pN0 pMXNo

Recurrence

73 16 16 0

M64 2 0 71 Caucasian 7 0 pT2b pN0 pMX No 71 63 63 0

Page 12: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

Recurrence

M65 2 0 66 Caucasian 7 0 pT2b pN0 pMX Unknown 66

M66 2 0 71 Caucasian 7 0 pT2b pN0 pMXNever

disease free

71 Never disease free

M67 0 0 59 Caucasian 9 0 pT3a pN0 pMX Unknown 59

M68 2 1 69 Caucasian 7 0 pT3b pN0 pMX Unknown 69

M69 2 1 72 Caucasian 6 0 pT3a pN0 pMXNo

Recurrence

72 123 123 0

M7 2 0 51 Caucasian 9 0 pT3a pN0 pMXNever

disease free

51 Never disease free

M70 2 0 65 Caucasian 6 0 pT2 pN0 pMXNever

disease free

65 Never disease free

M71 1 1 62 Caucasian 6 0 pT2b pN0 pMXNo

Recurrence

62 13 13 0

M72 2 0 65 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

65 83 83 0

M73 0 0 67 Caucasian 7 0 pT2b pN0 pMX Unknown 67

M74 0 0 60 Caucasian 5 0 pT2b pN0 pMXNo

Recurrence

61 134 134 0

M75 2 1 54 Caucasian 7 0 pT3a pN0 pMXNo

Recurrence

54 13 13 0

M76 0 0 73 Caucasian 6 0 pT3a pN0 pMX Never 73 Never

Page 13: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

disease free disease free

M77 2 0 65 Caucasian 7 0 pT2b pN0 pMX Recurred 65 51 51 1

M78 2 0 60 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

60 62 62 0

M79 2 0 50 Caucasian 6 0 pT3a pN0 pMXNo

Recurrence

50 11 11 0

M8 0 0 62 Caucasian 7 0 pT2b pN0 pMXNever

disease free

62 Never disease free

M80 2 0 66 Caucasian 7 0 pT2b pN0 pMXNo

Recurrence

66 10 10 0

M813 0

58 Caucasian 6 0 pT3a pN0 pMX Unknown 58

M823 0

67 Caucasian 6 0 pT3a pN0 pMX Recurred 67 135 135 1

M832 2

67 Caucasian 6 0 pT2b pN0 pMX Recurred 67 71 71 1

M843 2

64 African American 7 0 pT2b pN0 pM0

No Recurren

ce64 55 55 0

M852 1

70 Caucasian 7 0 pT3a pN0 pM0 Recurred 70 31 31 1

M862 1

62 Caucasian 7 0 pT2b pN0 pM0No

Recurrence

62 155 155 0

M872 0

76 Caucasian 7 0 pT3a pN0 pM0No

Recurrence

76 151 151 0

M883 1

57 Caucasian 7 0 pT3a pN0 pM0 Unknown 57

Page 14: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

M893 1

64 Caucasian 7 0 pT3b pN0 pM0 Unknown 64

M93 1

69 Caucasian 7 0 pT2b pN0 pMX Recurred 69 14 14 1

M903 0

70 Caucasian 7 0 pT3a pN0 pM0No

Recurrence

70 147 147 0

M912 0

62 Caucasian 7 0 pT2b pN0 pM0No

Recurrence

62 24 24 0

M921 0

65 Caucasian 7 0 pT2b pN0 pM0 Recurred 65 28 28 1

M930 0

66 Caucasian 7 0 pT3a pN0 pM0 Unknown 67

M943 1

70 Caucasian 7 -1 pT3a pNX pM0No

Recurrence

70 50 50 0

M953 1

73 Caucasian 6 0 pT3a pN0 pM0No

Recurrence

73 38 38 0

M963 1

59 African American 6 0 pT2b pN0 pMX

No Recurren

ce59 150 150 0

M970 0

63 Caucasian 7 0 pT2b pN0 pM0 Unknown 63

M982 1

68 Caucasian 6 0 pT2 pN0 pM0No

Recurrence

69 158 158 0

M99

1 0

70 Caucasian 8 0 pT3a pN0 pM0Never

disease free

70 Never disease free

N13 1

69 Caucasian 5 0 pT2a pNX pM0No

Recurrence

70 56 56 0

N101 0

69 Caucasian 8 0 pT3a pN0 pM0 Recurred 69 58 58 1

Page 15: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

N112 0

66 Caucasian 6 0 pT2a pN0 pM0 Unknown 66

N122 1

65 Caucasian 6 0 pT2b pN0 pM0No

Recurrence

65 48 48 0

N133 1

56 Caucasian 7 0 pT2a pN0 pM0 Recurred 56 38 38 1

N143 0

63 Caucasian 7 0 pT2a pN0 pM0 Recurred 63 115 115 1

N153 2

64 Caucasian 7 0 pT2b pN0 pM0 Unknown 64

N163 1

66 Caucasian 5 0 pT2a pN0 pM0No

Recurrence

66 17 17 0

N17

1 1

63 Caucasian 7 0 pT3a pN0 pM0Never

disease free

63 Never disease free

N18

1 0

55 Caucasian 6 0 pT2b pN0 pM0Never

disease free

55 Never disease free

N19

1 0

68 Caucasian 7 0 pT3b pNX pM0Never

disease free

68 Never disease free

N2

3 1

68 Caucasian 7 0 pT2a pN0 pM0Never

disease free

68 Never disease free

N20

1 0

62 Caucasian 7 0 pT2b pN0 pM0Never

disease free

62 Never disease free

N212 1

66 Caucasian 7 0 pT3a pN0 pM0 Recurred 66 27 27 1

N220 0

67 Caucasian 7 0 pT2b pN0 pM0 Unknown 67

Page 16: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

N23

3 1

52 Caucasian 7 0 pT3a pN0 pM0Never

disease free

52 Never disease free

N24

0 0

66 Caucasian 7 0 pT2b pN0 pM0Never

disease free

66 Never disease free

N25

0 0

65 Caucasian 5 0 pT2a pN0 pM0Never

disease free

65 Never disease free

N26

1 0

67 Caucasian 7 0 pT3a pN0 pM0Never

disease free

67 Never disease free

N272 3

65 Caucasian 8 0 pT3b pN0 pM0 Recurred 65 19 19 1

N28

2 1

66 Caucasian 7 0 pT2b pN0 pM0Never

disease free

66 Never disease free

N292 1

67 Other 7 0 pT3b pNX pM0No

Recurrence

67 16 16 0

N33 0

65 Caucasian 8 0 pT3b pN0 pM0 Unknown 65

N301 0

70 Caucasian 7 0 pT3b pN0 pM0 Recurred 70 28 28 1

N313 0

63 Caucasian 6 0 pT2b pN0 pM0 Recurred 63 33 33 1

N322 1

60 Caucasian 6 0 pT2b pNX pM0 Recurred 61 13 13 1

N33

0 1

67 Caucasian 5 0 pT2b pNX pM0Never

disease free

67 Never disease free

N34 2 1 66 Caucasian 7 0 pT2b pN0 pM0 No 66 69 69 0

Page 17: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

Recurrence

N352 0

76 Caucasian 6 0 pT2b pN0 pM0No

Recurrence

76 106 106 0

N362 1

59 Caucasian 6 0 pT3a pN0 pM0 Recurred 59 12 12 1

N37

2 0

69 Caucasian 6 0 pT2b pN0 pM0Never

disease free

70 Never disease free

N38 3 0 59 Other 6 0 pT2b pN0 pM0 Recurred 59 68 68 1

N393 3

60 Caucasian 7 0 pT3a pN0 pM0No

Recurrence

60 72 72 0

N4

3 2

68 Caucasian 7 0 pT2b pN0 pM0Never

disease free

69 Never disease free

N403 0

79 Caucasian 8 0 pT2b pN0 pM0 Unknown 79

N411 0

65 Caucasian 7 0 pT3b pNX pM0 Unknown 65

N42

0 0

79 Caucasian 7 0 pT2b pNX pM0Never

disease free

79 Never disease free

N433 1

73 Caucasian 7 0 pT2b pN0 pM0 Unknown 73

N443 2

68 Caucasian 6 0 pT2b pN0 pM0 Unknown 68

N453 0

57 Caucasian 8 0 pT3a pN0 pM0No

Recurrence

57 69 69 0

N462 1

71 Caucasian 7 0 pT3a pN0 pM0 Recurred 71 23 23 1

Page 18: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

N472 0

64 Caucasian 8 0 pT1b pN0 pM0 Recurred 64 14 14 1

N48

0 0

66 Caucasian 6 0 pT2a pN0 pM0Never

disease free

66 Never disease free

N493 1

67 Caucasian 7 0 pT3b pN0 pM0 Unknown 67

N53 0

60 Caucasian 6 0 pT2a pN0 pM0No

Recurrence

60 23 23 0

N502 0

63 Caucasian 6 0 pT2a pN0 pMX Unknown 63

N510 0

69 Caucasian 7 0 pT2b pN0 pM0 Unknown 69

N522 0

68 Caucasian 7 0 pT3a pN0 pM0 Unknown 68

N530 0

69 Caucasian 7 0 pT3b pN0 pM0 Unknown 69

N543 3

65 Caucasian 7 0 pT2b pN0 pM0No

Recurrence

65 72 72 0

N550 0

64 Caucasian 5 0 pT2a pN0 pM0 Unknown 64

N560 0

63 Caucasian 5 0 pT2b pN0 pM0No

Recurrence

63 11 11 0

N57

1 1

73 Caucasian 7 0 pT3a pN0 pM0Never

disease free

73 Never disease free

N583 2

66 Caucasian 9 0 pT3b pNX pM0 Unknown 66

N592 1

64 Caucasian 6 0 pT3a pNX pM0No

Recurrence

64 131 131 0

N6 0 1 70 Caucasian 5 0 pT2a pN0 pM0 No 70 34 34 0

Page 19: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

Recurrence

N603 0

55 Caucasian 5 0 pT2b pN0 pM0No

Recurrence

55 71 71 0

N611 0

67 African American 7 0 pT3a pNX pM0 Unknown 67

N620 0

63 Caucasian 7 0 pT2b pN0 pM0 Unknown 63

N63 3 2 67 Other 7 1 pT3b pN1 pM0 Unknown 67

N643 1

66 Caucasian 7 0 pT3b pN0 pM0 Recurred 66 8 8 1

N65 0 0 73 Other 7 0 pT2b pN0 pM0 Recurred 73 14 14 1

N662 0

64 Caucasian 8 0 pT3a pN0 pM0 Unknown 64

N673 0

76 Caucasian 7 0 pT2b pN0 pM0 Recurred 77 8 8 1

N682 0

65 Caucasian 5 0 pT2a pN0 pM0No

Recurrence

65 102 102 0

N69

2 1

70 Caucasian 7 0 pT2b pN0 pM0Never

disease free

70 Never disease free

N72 1

60 Caucasian 6 0 pT2b pN0 pM0No

Recurrence

60 117 117 0

N702 1

68 Caucasian 5 0 pT2b pN0 pM0No

Recurrence

68 93 93 0

N710 0

65 African American 6 0 pT3a pNX pM0 Unknown 65

N720 0

65 Caucasian 7 0 pT2b pN0 pM0No

Recurrence

65 26 26 0

N733 1

71 Caucasian 7 0 pT2b pN0 pM0 Never disease 71 Never

disease free

Page 20: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

free

N74

3 0

72 African American 9 0 pT3a pN0 pM0

Never disease

free72 Never

disease free

N75

2 0

70 Caucasian 7 0 pT3a pN0 pM0Never

disease free

70 Never disease free

N763 0

70 Caucasian 7 0 pT3a pN0 pM0 Unknown 70

N80 0

64 Caucasian 7 0 pT3a pN0 pM0 Recurred 64 36 36 1

N90 0

58 Caucasian 6 0 pT2a pN0 pM0No

Recurrence

58 15 15 0

P12 0

70 Caucasian 7 0 pT2a pN0 pM0 Unknown 70

P103 0

70 Caucasian 7 0 pT3a pN0 pMX Unknown 70

P110 0

62 Caucasian 9 1 pT3b pN1 pMX Unknown 62

P120 0

65 Caucasian 7 0 pT3b pN0 pMX Unknown 65

P131 0

59 Caucasian 6 0 pT2 pN0 pM0 Unknown 59

P143 1

63 Caucasian 8 0 pT2b pN0 pMX Unknown 64

P151 0

57 Caucasian 6 0 pT2b pN0 pMX Unknown 57

P162 0

66 Caucasian 8 0 pT2b pN0 pMX Unknown 67

P173 0

62 Caucasian 7 0 pT3b pN0 pMX Unknown 62

P180 0

64 Caucasian 7 0 pT3a pN0 pMX Unknown 64

Page 21: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

P193 2

73 Caucasian 7 0 pT3a pN0 pMX Unknown 73

P22 0

71 Caucasian 7 0 pT2b pN0 pMX Unknown 71

P20

3 1

71 Caucasian 8 0 pT3a pN0 pMXNever

disease free

72 Never disease free

P21

1 1

65 Caucasian 7 0 pT2b pN0 pMXNever

disease free

65 Never disease free

P223 2

58 Caucasian 7 0 pT3a pN0 pMX Unknown 58

P233 2

68 Caucasian 7 0 pT3a pN0 pMX Unknown 68

P24

3 3

66 Caucasian 7 0 pT2b pN0 pMXNever

disease free

66 Never disease free

P253 1

65 Caucasian 8 0 pT2b pN0 pMX Unknown 65

P262 1

77 Caucasian 9 1 pT3a pN1 pMX Unknown 78

P273 1

70 Caucasian 7 0 pT2a pN0 pMX Unknown 70

P280 1

70 Caucasian 6 0 pT2b pN0 pMX Unknown 70

P291 1

73 Caucasian 6 0 pT2b pN0 pMX Unknown 74

P30 0

55 Caucasian 7 0 pT2a pN0 pMX Unknown 55

P303 1

72 Caucasian 7 0 pT2a pN0 pM0 Unknown 72

P310 0

61 Caucasian 6 0 pT3 pN0 pMX Unknown 61

Page 22: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

P322 1

64 African American 6 0 pT2b pN0 pMX Unknown 65

P332 1

60 African American 7 0 pT3a pN0 pMX Recurred 60 8 8 1

P343 2

60 Caucasian 9 0 pT3b pN0 pMX Unknown 60

P353 1

70 Caucasian 8 0 pT2a pN0 pMX Unknown 70

P363 1

62 Caucasian 7 0 pT3a pN0 pMX Unknown 62

P373 0

75 Caucasian 9 0 pT3a pN0 pMX Unknown 75

P383 1

67 Caucasian 9 0 pT4 pN0 pMX Unknown 67

P390 0

73 Caucasian 7 0 pT3a pN0 pMX Unknown 73

P41 0

69 Caucasian 7 0 pT2a pN0 pMX Unknown 69

P403 2

67 Caucasian 7 0 pT2a pN0 pMX Unknown 67

P52 0

61 Caucasian 7 0 pT2b pN0 pMX Unknown 61

P62 2

64 Caucasian 7 0 pT2b pN0 pMX Unknown 65

P73 0

54 Caucasian 7 0 pT2b pN0 pMX Unknown 54

P80 0

56 Caucasian 7 0 pT2a pN0 pMX Unknown 56

P90 0

69 Caucasian 7 0 pT2b pN0 pM0 Unknown 69

184 Caucasian 5 pT2a pNo

379 Caucasian 9 pT2a pN0

Page 23: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

454 Caucasian 5 pT2c pNo

971 Caucasian 5 pT2 pNo

982 Caucasian 7 pT3b pNo

1084 Caucasian 7 pT2a pNo

1167 Caucasian 5 pT2a pNo

1168 Caucasian 7 pT2b pNo

1413 Caucasian 5 PT2c PNo

1640 Caucasian 6 PT2a PNo

2155 Caucasian 9 pT2c pNo

2323 Caucasian 8 pT3b pNo

2490 Caucasian 7 pT2a pNo

2765 Caucasian 7 pT3a pNo

2913 Caucasian 9 pT3 pNo

2914 Caucasian 7 pT2c pNo

3710 Caucasian 5 pT2c pNo

4177 Caucasian 7 pT3a pNx

4389 Caucasian 5 pT2a pNo

Page 24: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

4549 Caucasian 5 pT2c pNo

4626 Caucasian 8 pT3b pN1

5025 Caucasian 8 PT3a PNo

5188 Caucasian 6 pT2c pNo

5231 Caucasian 7 pT3b pNo

5811 Caucasian 9

6083 Caucasian 6

6084 Caucasian 7 pT2c pN0

6085 Caucasian 7 pT2c pN0

6316 Caucasian 6 pT2c pN0

6514 Caucasian 7 pT2a pN0

6530 Caucasian 7 pT3a pN0

7307 Caucasian 8 pT3b pN0

7911 Caucasian 6 pT2c pNx

8055 Caucasian 6 pT2c pN0

8225 Caucasian 8 pT2c pN0

8233 Caucasian 6 pT2c pN0

Page 25: link.springer.com10.1007/s00210... · Web viewTabella 1S. Clinico-pathological caratheristics of prostate cancer patients analysed in TMAs Tissue code NM23-H1 cyt. staining NM23-H1

10159 Caucasian 6 pT2c pN0

10888 Caucasian 6 pT2a pN0

11531 Caucasian 7 pT2b pN0

12266 Caucasian 6 pT2c pNo

12623 Caucasian 6 pT2 pNo

12626 Caucasian 5 pT2 pNo

12802 Caucasian 4 pT2a pNo

14967 Caucasian 5 pT2c pNx

15619 Caucasian 5 pT2c pN0

13426/0 Caucasian 4 pT2a pN0